Title:
SCLERAL LIPID METABOLIC PATHWAY INTERVENTION REGULATOR OR APPLICATION OF LIPID METABOLISM REGULATING DRUG AS DRUG FOR INHIBITING MYOPIA AMETROPIA AND AXIS OCULI EXTENSION
Document Type and Number:
WIPO Patent Application WO/2022/057234
Kind Code:
A1
Abstract:
A scleral lipid metabolic pathway intervention regulator or an application of a lipid metabolism regulating drug as a drug for inhibiting myopia ametropia and axis oculi extension. By means of a myopia mouse RNA-seq experiment, it is discovered that a scleral lipid metabolic pathway is significantly reduced, and the gene expression of a plurality of key enzymes in the lipid metabolic pathway is reduced. By means of a myopia sclera electron microscope, lipid droplet deposition is observed and discovered, which further indicates that the lipid metabolism in myopia sclera is abnormal, and the scleral lipid metabolism is regulated by means of ω-3, so that myopia ametropia and axis oculi extension can be effectively inhibited.
More Like This:
Inventors:
ZHOU XIANGTIAN (CN)
PAN MIAOZHEN (CN)
QU JIA (CN)
PAN MIAOZHEN (CN)
QU JIA (CN)
Application Number:
PCT/CN2021/083739
Publication Date:
March 24, 2022
Filing Date:
March 30, 2021
Export Citation:
Assignee:
UNIV WENZHOU MEDICAL (CN)
International Classes:
A61P27/02; A61K31/20; A61P27/10
Domestic Patent References:
| WO2015165507A1 | 2015-11-05 |
Foreign References:
| CN112057444A | 2020-12-11 | |||
| JP2020138964A | 2020-09-03 |
Other References:
WU, JING-RUI ET AL.: "The Combined Effect of ω-3 Fatty Acid and Lutein on the Vision of Young Children", ACTA NUTRIMENTA SINICA, vol. 40, no. 5, 31 December 2018 (2018-12-31), pages 503 - 505, XP055912913
Attorney, Agent or Firm:
WENZHOU JINOU PATENT LAW OFFICE (GENERAL PARTNERSHIP) (CN)
Download PDF: